We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$673M
AUM Growth
+$87.3M
Cap. Flow
+$52.4M
Cap. Flow %
7.78%
Top 10 Hldgs %
60.63%
Holding
55
New
16
Increased
9
Reduced
7
Closed
18

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$37.4M
2
EXEL icon
Exelixis
EXEL
+$24.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$20M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$16.9M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$32.9M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$17.3M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$15M
4
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$13.8M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 83.75%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
26
Vanda Pharmaceuticals
VNDA
$307M
$5.22M 0.78%
309,800
-487,731
-61% -$8.16M
ACOR
27
PUT
DELISTED
Acorda Therapeutics
ACOR
$4.73M 0.7%
1,667
– –
AMRN
28
CALL
Amarin Corp
AMRN
$299M
$3.3M 0.49%
+54,810
New +$4.07M
AMRN
29
Amarin Corp
AMRN
$299M
$3.18M 0.47%
52,841
– –
YARW
30
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$1.95M 0.29%
+14
New +$1.7M
LUMO
31
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.69M 0.25%
25,944
-194,845
-88% -$13.8M
ATRS
32
DELISTED
Antares Pharma, Inc.
ATRS
$1.1M 0.16%
+500,000
New +$1.13M
ARNA
33
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$604K 0.09%
+15,300
New +$595K
ACOR
34
CALL
DELISTED
Acorda Therapeutics
ACOR
$449K 0.07%
+158
New +$473K
GBT
35
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$275K 0.04%
+5,700
New +$318K
STRM
36
DELISTED
Streamline Health Solutions
STRM
$239K 0.04%
8,676
– –
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
– –
-40,000
Closed -$5.44M
CRBP icon
38
Corbus Pharmaceuticals
CRBP
$166M
– –
-20,000
Closed -$4.26M
DBVT
39
DBV Technologies
DBVT
$799M
– –
-31,314
Closed -$7.7M
INCY icon
40
Incyte
INCY
$24.2B
– –
-70,323
Closed -$6.66M
RNAC icon
41
Cartesian Therapeutics
RNAC
$229M
– –
-5,930
Closed -$1.75M
SAGE
42
DELISTED
Sage Therapeutics
SAGE
– –
-200,000
Closed -$32.9M
WVE icon
43
Wave Life Sciences
WVE
$1.09B
– –
-331,085
Closed -$11.6M
RVNC
44
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-300,000
Closed -$10.7M
JNCE
45
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-292,673
Closed -$3.73M
SIOX
46
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-356,250
Closed -$15M
MYOV
47
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-160,530
Closed -$2.03M
CNCE
48
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-669,472
Closed -$17.3M
GBT
49
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$7.87M
KDMN
50
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-840,303
Closed -$3.04M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Great Point Partners held 55 positions worth $673M, up 15% from $586M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Great Point Partners deployed $52.4M of net new capital in Q1 2018, opening 16 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 500,000 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lumos Pharma, Inc. Common Stock, an estimated $13.8M trimmed.

  • Great Point Partners's largest Q1 2018 buy was Puma Biotechnology: 500,000 shares worth $34M.
  • Great Point Partners added most to Iovance Biotherapeutics in Q1 2018, an estimated $20M increase.
  • Great Point Partners's biggest Q1 2018 reduction was Lumos Pharma, Inc. Common Stock, cutting an estimated $13.8M.
  • Great Point Partners fully exited Sage Therapeutics in Q1 2018, selling an estimated $32.9M.
  • Great Point Partners's ten largest holdings make up 61% of its $673M portfolio in Q1 2018.
  • Great Point Partners opened 16 new positions and closed 18 in Q1 2018.
  • Great Point Partners's portfolio value rose 15% quarter-over-quarter to $673M.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.